EC OKs AbbVie’s, Biogen’s MS Drug Zinbryta
The European Commission (EC) has granted marketing authorization to AbbVie’s and Biogen’s Zinbryta (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Zinbryta is a once-monthly, self-administered, subcutaneous injection.
Zinbryta is also approved in the United States and is under regulatory review in Switzerland, Canada, and Australia.
Zinbryta is a humanized IgG1 monoclonal antibody that selectively binds to the high-affinity interleukin-2 receptor subunit (CD25). CD25 is expressed at high levels on T-cells that become activated in people with MS.
